1. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.
- Author
-
Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, and Jain RK
- Subjects
- Adipose Tissue metabolism, Angiotensin II Type 1 Receptor Blockers pharmacology, Animals, Body Mass Index, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal pathology, Combined Modality Therapy, Diet, High-Fat adverse effects, Disease Models, Animal, Disease Progression, Fibrosis, Genetic Predisposition to Disease, Humans, Interleukin-1beta metabolism, Male, Mice, Mice, Knockout, Models, Biological, Neutrophils immunology, Neutrophils metabolism, Obesity etiology, Pancreatic Neoplasms etiology, Signal Transduction drug effects, Tumor Burden, Tumor Microenvironment, Drug Resistance, Neoplasm drug effects, Inflammation etiology, Inflammation pathology, Obesity complications, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Receptor, Angiotensin, Type 1 metabolism
- Abstract
Unlabelled: It remains unclear how obesity worsens treatment outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). In normal pancreas, obesity promotes inflammation and fibrosis. We found in mouse models of PDAC that obesity also promotes desmoplasia associated with accelerated tumor growth and impaired delivery/efficacy of chemotherapeutics through reduced perfusion. Genetic and pharmacologic inhibition of angiotensin-II type-1 receptor reverses obesity-augmented desmoplasia and tumor growth and improves response to chemotherapy. Augmented activation of pancreatic stellate cells (PSC) in obesity is induced by tumor-associated neutrophils (TAN) recruited by adipocyte-secreted IL1β. PSCs further secrete IL1β, and inactivation of PSCs reduces IL1β expression and TAN recruitment. Furthermore, depletion of TANs, IL1β inhibition, or inactivation of PSCs prevents obesity-accelerated tumor growth. In patients with pancreatic cancer, we confirmed that obesity is associated with increased desmoplasia and reduced response to chemotherapy. We conclude that cross-talk between adipocytes, TANs, and PSCs exacerbates desmoplasia and promotes tumor progression in obesity., Significance: Considering the current obesity pandemic, unraveling the mechanisms underlying obesity-induced cancer progression is an urgent need. We found that the aggravation of desmoplasia is a key mechanism of obesity-promoted PDAC progression. Importantly, we discovered that clinically available antifibrotic/inflammatory agents can improve the treatment response of PDAC in obese hosts. Cancer Discov; 6(8); 852-69. ©2016 AACR.See related commentary by Bronte and Tortora, p. 821This article is highlighted in the In This Issue feature, p. 803., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF